 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 October 1997 | Volume 127 Issue 7 | Pages 501-508
Objective: To estimate the relative risk for incident acute myocardial infarction in relation to the current use of estrogen and estrogen-progestogen.
Design: Retrospective case–control study.
Setting: Medical centers of a large prepaid health care program, the kaiser Permanente Medical Care Program (KPMCP), Northern California region.
Participants: All women hospitalized at a KPMCP center for incident acute myocardial infarction during a 3-year period from 1991 to 1994. Controls were matched to case-patients for year of birth and KPMCP facility and were selected at random from among all female members of the KPMCP.
Intervention: An in-person interview that included questions about current and lifetime use of estrogen and estrogen-progestogen; known cardiovascular risk factors; and other medical, sociodemographic, and behavioral factors that might affect risk for myocardial infarction.
Main Outcome Measure: Odds ratios for myocardial infarction associated with use of estrogen and estrogen-progestogen.
Results: The odds ratio for myocardial infarction in current users of estrogen or estrogen-progestogen compared with women who had never used these agents was 0.96 (95% CI, 0.66 to 1.40) after adjustment for confounders. The odds ratio for myocardial infarction in past users of estrogen or estrogen-progestogen was 1.07 (CI, 0.72 to 1.58). Duration of hormone use was unrelated to the odds ratio for myocardial infarction.
Conclusions: This study did not show a statistically significant decrease in the odds ratio for myocardial infarction associated with current use of estrogen or estrogen-progestogen. It neither confirms nor refutes the hypothesis that hormone use prevents myocardial infarction in postmenopausal women.
Author and Article Information
From the Kaiser Permanente Medical Care Program, Oakland, California.see end of text.
ARTICLE
Myocardial Infarction and the Use of Estrogen and Estrogen-Progestogen in Postmenopausal Women
Acknowledgments: The authors thank Teresa Picchi and Luisa Hamilton for overseeing field operations and Kimberly Tolan for computer programming.
Grant Support: By grant R01-HL-47043 from the National Heart. Lung, and Blood Institute.
Requests for Reprints: Stephen Sidney, MD. Kaiser Permanente Medical Care Program, Division of Research, 3505 Broadway. Oakland, CA 94611-5714.
Current Author Addresses: Drs. Sidney and Quesenberry: Kaiser Permanente Medical Care Program. Division of Research, 3505 Broadway, Oakland, CA 94611-5714.
This article has been cited by other articles:
|
|
 |
|
  P. Ouyang, E. D. Michos, and R. H. Karas Hormone Replacement Therapy and the Cardiovascular System: Lessons Learned and Unanswered Questions J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1741 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Prentice, R. Langer, M. L. Stefanick, B. V. Howard, M. Pettinger, G. Anderson, D. Barad, J. D. Curb, J. Kotchen, L. Kuller, et al. Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial Am. J. Epidemiol., September 1, 2005; 162(5): 404 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Coronary Heart Disease Obstet. Gynecol., October 1, 2004; 104(4_suppl): 41S - 48S. [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh and I. Sakuma Should Progestins Be Blamed for the Failure of Hormone Replacement Therapy to Reduce Cardiovascular Events in Randomized Controlled Trials? Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1171 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Petitti Commentary: Hormone replacement therapy and coronary heart disease: four lessons Int. J. Epidemiol., June 1, 2004; 33(3): 461 - 463. [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Kannel and D. Levy Menopause, Hormones, and Cardiovascular Vulnerability in Women Arch Intern Med, March 8, 2004; 164(5): 479 - 481. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Garbe and S. Suissa Issues to debate on the Women's Health Initiative (WHI) study: Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies Hum. Reprod., January 1, 2004; 19(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Col and S. G. Pauker The Discrepancy between Observational Studies and Randomized Trials of Menopausal Hormone Therapy: Did Expectations Shape Experience? Ann Intern Med, December 2, 2003; 139(11): 923 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Grodstein, J. E. Manson, and M. J. Stampfer Postmenopausal Hormone Replacement Therapy Ann Intern Med, April 15, 2003; 138(8): 688 - 688. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grodstein, T. B. Clarkson, and J. E. Manson Understanding the Divergent Data on Postmenopausal Hormone Therapy N. Engl. J. Med., February 13, 2003; 348(7): 645 - 650. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grodstein and J. E. Manson Relationship Between Hormone Replacement Therapy, Socioeconomic Status, and Coronary Heart Disease JAMA, January 1, 2003; 289(1): 44 - 44. [Full Text] [PDF]
|
|
|
|
|
|
H. D. Nelson, L. L. Humphrey, P. Nygren, S. M. Teutsch, and J. D. Allan Postmenopausal Hormone Replacement Therapy: Scientific Review JAMA, August 21, 2002; 288(7): 872 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Humphrey, B. K.S. Chan, and H. C. Sox Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease Ann Intern Med, August 20, 2002; 137(4): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Christian, S. Harrington, W. D. Edwards, A. L. Oberg, and L. A. Fitzpatrick Estrogen Status Correlates with the Calcium Content of Coronary Atherosclerotic Plaques in Women J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1062 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. LaRosa Prevention and Treatment of Coronary Heart Disease: Who Benefits? Circulation, October 2, 2001; 104(14): 1688 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh, D. K. Jin, S. H. Yang, S.-K. Lee, H. Y. Hwang, M. H. Kang, W. Kim, D. S. Kim, I. S. Choi, and E. K. Shin Vascular Effects of Synthetic or Natural Progestagen Combined With Conjugated Equine Estrogen in Healthy Postmenopausal Women Circulation, April 17, 2001; 103(15): 1961 - 1966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Grodstein, J. E. Manson, G. A. Colditz, W. C. Willett, F. E. Speizer, and M. J. Stampfer A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease Ann Intern Med, December 19, 2000; 133(12): 933 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. McNagny Prescribing Hormone Replacement Therapy for Menopausal Symptoms Ann Intern Med, October 19, 1999; 131(8): 605 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Herrington The HERS Trial Results: Paradigms Lost? Ann Intern Med, September 21, 1999; 131(6): 463 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.M. Herrington and C.D. Furberg Hormone therapy: time for replacement? Eur. Heart J., September 2, 1999; 20(18): 1285 - 1286. [PDF]
|
|
|
|
 |
|
 J. V. Pinkerton and R. Santen Alternatives to the Use of Estrogen in Postmenopausal Women Endocr. Rev., June 1, 1999; 20(3): 308 - 320. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Santen and G. R. Petroni Relative Versus Attributable Risk of Breast Cancer from Estrogen Replacement Therapy J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1875 - 1881. [Full Text]
|
|
|
|
|
|
N. L. Keating, P. D. Cleary, A. S. Rossi, A. M. Zaslavsky, and J. Z. Ayanian Use of Hormone Replacement Therapy by Postmenopausal Women in the United States Ann Intern Med, April 6, 1999; 130(7): 545 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cushman, E. N. Meilahn, B. M. Psaty, L. H. Kuller, A. S. Dobs, and R. P. Tracy Hormone Replacement Therapy, Inflammation, and Hemostasis in Elderly Women Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 893 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. X. Pan, J. Boal, for the Geriatrics Journal Club, E. Banks, V. Beral, P. J. L. Ong, M. B. Sorensen, C. S. Hayward, C. M. Webb, P. Collins, et al. Hormone Replacement Therapy for Secondary Prevention of Coronary Heart Disease JAMA, March 3, 1999; 281(9): 794 - 797. [Full Text] [PDF]
|
|
|
|
|
|
S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, E. Vittinghoff, and for the Heart and Estrogen/progestin Replacement S Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women JAMA, August 19, 1998; 280(7): 605 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Petitti Hormone Replacement Therapy and Heart Disease Prevention: Experimentation Trumps Observation JAMA, August 19, 1998; 280(7): 650 - 652. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Fitzpatrick and M. D. Editorial: Coronary Artery Disease in Women--an Equal Opportunity Killer J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 719 - 720. [Full Text]
|
|
|
|
 |
|
 Does Postmenopausal Hormone Replacement Prevent MI? Journal Watch Cardiology, November 10, 1997; 1997(1110): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Does Hormone Therapy Really Prevent MI? Journal Watch Women's Health, November 1, 1997; 1997(1101): 4 - 4. [Full Text]
|
|
|
|
 |
|
 ERT AND MI: LACK OF PROTECTION? Journal Watch (General), October 14, 1997; 1997(1014): 4 - 4. [Full Text]
|
|
Article
